600079 Humanwell Healthcare
- 19.30
- -0.01-0.05%
Humanwell Healthcare News
Investors in Humanwell Healthcare (Group)Ltd (SHSE:600079) Have Seen Decent Returns of 97% Over the Past Five Years
When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, long term
Humanwell Healthcare's Unit Gets FDA's Nod to Market Two Drugs
The US Food and Drug Administration approved the application of Humanwell Healthcare Group's (SHA:600079) unit, Epic Pharma, for two drugs, the company said in its filing on the Shanghai Stock Exchang
Humanwell Healthcare's Unit Gets Nod to Strengthen Oxycodone Hydrochloride Tablets' Dosage
Chinese drug regulator National Medical Products Administration approved the application of Yichang Humanwell Pharmaceutical, a unit of Humanwell Healthcare Group (SHA:600079), to increase the strengt
Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Shares Lagging The Market But So Is The Business
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) as a highly attractive investment w
Could The Market Be Wrong About Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) Given Its Attractive Financial Prospects?
Humanwell Healthcare (Group)Ltd (SHSE:600079) has had a rough three months with its share price down 24%. However, stock prices are usually driven by a company's financial performance over the long
China Approves Sale of Humanwell Healthcare Unit's Prostate Cancer Treatment
China's medical products administrator granted Humanwell Healthcare Group (SHA:600079) unit Yichang Renfu Pharmaceutical a drug registration certificate for its enzalutamide soft capsules, according t
Renfu Pharmaceutical (600079.SH): Enzalutamide softgels obtained drug registration certificate
Gelonghui, March 5 | Renfu Pharmaceutical (600079.SH) announced that Yichang Renfu recently received the “Drug Registration Certificate” for enzalumide softgels approved and issued by the State Drug Administration. Enzalutamide is an androgen receptor inhibitor suitable for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CPRC) with a high risk of metastatic metastasis; it is also suitable for the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms after failure of androgen deprivation therapy (ADT) and have not received chemotherapy.
Production Line of Humanwell Healthcare's Unit Passes UK Drug Regulator's Inspection
Humanwell Healthcare Group's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, obtained a good manufacturing practice certificate from the UK's drug regulator after its production line in China's H
Renfu Pharmaceutical (600079.SH) subsidiary's freeze-dried powder injection production line passed the British GMP compliance inspection
Renfu Pharmaceutical (600079.SH) was released Recently, Yichang Renfu, a holding subsidiary of the company, received British Pharmaceuticals and Health Products...
Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Humanwell Healthcare's Subsidiary Gets Nod to Register Anesthesia Drug
Humanwell Healthcare Group's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for remifentanil
Renfu Pharmaceutical (600079.SH): Injectable remifentanil hydrochloride increases indications and obtains drug registration certificate
On February 20, Ge Longhui Pharmaceutical (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (referred to as “Yichang Renfu”, the company holds 80% of its shares) recently received a “Drug Registration Certificate” for injectable remifentanil hydrochloride approved and issued by the State Drug Administration. Remifentanil is a μ-opioid receptor agonist. Yichang Renfu's injectable remifentanil hydrochloride was approved for marketing in 2003. The indications are “induction of total anesthesia and maintenance of analgesia during total anesthesia”. Yichang Renfu submitted remifentanil hydrochloride for injection to the State Drug Administration in December 2022
Humanwell Healthcare (Group)Ltd's (SHSE:600079) Earnings Growth Rate Lags the 15% CAGR Delivered to Shareholders
Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) shareholders might be concerned after seeing the share price drop 22% in the last month. But that doesn't change the fact that the returns over t
Humanwell Unit Gets China Registration Certificate for Drug to Prevent Renal Allograft Rejection
Humanwell Healthcare Group (SHA:600079) unit, Yichang Humanwell Pharmaceutical, received a certificate from China's National Medical Products Administration for the registration of its enteric-coated
Renfu Pharmaceutical (600079.SH): Mycophenol sodium enteric tablets obtained drug registration certificate
Gelonghui, January 22丨Renfu Pharmaceutical (600079.SH) announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (referred to as “Yichang Renfu”, the company holds 80% of its shares) recently received a “Drug Registration Certificate” for mescopol sodium enteric tablets approved and issued by the State Drug Administration. Micofol sodium enteric tablets are suitable for use with ciclosporin and corticosteroids to prevent acute rejection in adult patients undergoing allogeneic kidney transplantation.
Renfu Pharmaceutical (600079.SH): Peony licorice granules obtained drug registration certificate
Gelonghui, January 10 | Renfu Pharmaceutical (600079.SH) announced that Wuhan Kangle Pharmaceutical Co., Ltd. (“Kangle Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for peony licorice granules approved and issued by the State Drug Administration. The drug's function is to nourish the blood and relieve pain; it is used for symptoms of contracture pain caused by insufficient negative blood flow and muscular dystrophy; symptoms include leg and foot cramps and abdominal pain.
Renfu Pharmaceutical (600079.SH): Morphone hydrochloride extended-release tablets obtained drug registration certificate
On January 8, Ge Longhui Pharmaceutical (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Registration Certificate” for hydromorphone hydrochloride extended-release tablets approved and issued by the State Drug Administration. Hydromorphone hydrochloride extended-release tablets are suitable for treating severe pain in adults.
Humanwell Healthcare Gets Registration Approval for Pain Medication
Humanwell Healthcare Group (SHA:600079) has obtained approval from China's National Medical Products Administration to register its Aminophen Oxycodone tablets, a prescription medication for moderate
Renfu Pharmaceutical (600079.SH): Aminophenol oxycodone tablets obtained drug registration certificate
Gelonghui January 4 丨 Renfu Pharmaceutical (600079.SH) announced that its holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., recently received the “Drug Registration Certificate” for aminophenol oxycodone tablets approved and issued by the State Drug Administration. Aminophenol oxycodone tablets are suitable for the treatment of moderate to severe pain that is severe enough to require the use of opioid analgesics and lack of alternative treatments.
Enhua Pharmaceutical, which is in the second tier of anesthesia, has cut the cake of Renfu Pharmaceutical
“Investor Network” Choi Chun Enhua Pharmaceutical (002262.SZ, hereinafter referred to as the “Company”) welcomed two good news. In December, the company announced that it received a notice from the US Food and Drug Administration (FDA). The FDA completed the evaluation of the company's corrective measures and closed a warning letter to the company's Jiawang API factory. In 2019, during an inspection, the FDA discovered that the products sold by the company's Jiawang Pharmaceutical Factory to the US were inadequate, including flawed implementation methods and standards, and issued a warning letter. In the same month, the company announced that its innovative drug, oxelidine fumarate injection, was included in the national medical insurance catalogue. In the first three quarters of this year, the company's operating income was attributed to
Analysis
Price Target
No Data
